BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30485408)

  • 41. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
    Gloghini A; Bosco A; Ponzoni M; Spina M; Carbone A
    Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
    Hartmann S; Plütschow A; Mottok A; Bernd HW; Feller AC; Ott G; Cogliatti S; Fend F; Quintanilla-Martinez L; Stein H; Klapper W; Möller P; Rosenwald A; Engert A; Hansmann ML; Eichenauer DA
    Am J Hematol; 2019 Nov; 94(11):1208-1213. PubMed ID: 31396979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
    Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
    Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.
    Shankar AG; Kirkwood AA; Depani S; Bianchi E; Hayward J; Ramsay AD; Hall GW
    Br J Haematol; 2016 May; 173(3):421-31. PubMed ID: 26996288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
    Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
    Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site.
    Cotta CV; Coleman JF; Li S; Hsi ED
    Histopathology; 2011 Dec; 59(6):1194-203. PubMed ID: 22175899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
    Eichenauer DA; Fuchs M
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.
    Akhtar S; Rauf MS; Khafaga Y; Al-Kofide A; Elhassan TAM; Elshenawy MA; Nadri J; Mushtaq AH; Bakshi N; Shamayel M; Al-Sweedan S; Sarwar S; Maghfoor I
    BMC Cancer; 2021 Apr; 21(1):351. PubMed ID: 33794818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nodular lymphocyte-predominant hodgkin lymphoma.
    Tsai HK; Mauch PM
    Semin Radiat Oncol; 2007 Jul; 17(3):184-9. PubMed ID: 17591565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
    Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
    J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology.
    Hartmann S; Eray M; Döring C; Lehtinen T; Brunnberg U; Kujala P; Vornanen M; Hansmann ML
    BMC Cancer; 2014 May; 14():332. PubMed ID: 24885870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of c-FLIP in classic and nodular lymphocyte-predominant Hodgkin lymphoma.
    Uherova P; Olson S; Thompson MA; Juskevicius R; Hamilton KS
    Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):105-10. PubMed ID: 15354734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Agbay RLMC; Loghavi S; Zuo Z; Fayad L; Dabaja B; Medeiros LJ; Khoury JD
    Am J Surg Pathol; 2018 Apr; 42(4):492-499. PubMed ID: 29309302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The spectrum of nodular lymphocyte predominant Hodgkin lymphoma: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
    Hartmann S; Dojcinov S; Dotlic S; Gibson SE; Hsi ED; Klapper W; Klimkowska M; Pinilla SMR; Richter J; Sabattini E; Tousseyn T; de Jong D
    Virchows Arch; 2023 Oct; 483(4):451-463. PubMed ID: 37530790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.